Clinical Trial Update: To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing CT-P13 (biosimilar infliximab) to China-approved Remicade when co-administered with methotrexate in active rheumatoid arthritis; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CT-P13 (infliximab biosimilar)
• Remicade (infliximab)

Snippet

Sponsor: Celltrion | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED